SER — Serina Therapeutics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1708599 ·
Last close
$2.14
Market Cap
$32.09M
52W High
$2.30
52W Low
$1.49
ADV30
112,017
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,280,000 | -6,898,000 | 27,299,000 | 24,526,000 | 9,671,000 |
| Dec 2025 | 0 | — | -6,207,000 | -3,336,000 | 6,951,000 | 3,056,000 | 6,988,000 |
| Sep 2025 | 0 | — | -6,392,000 | -4,585,000 | 12,413,000 | 8,620,000 | 10,819,000 |
| Jun 2025 | 0 | — | -5,565,000 | -6,448,000 | 8,941,000 | 6,041,000 | 7,295,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,201,000
Investing CF
$-84,000
Financing CF
$38,552,000
CapEx
$-46,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.18
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-70,398,000
Inventory
—
Receivables
$14,000
ST Investments
$0
EBIT TTM
$-20,864,000
Pretax Income TTM
$-21,266,000
Interest Exp TTM
$402,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$130,000
EBITDA
$-24,370,000
Free Cash Flow
$-7,958,750
Enterprise Value
$16,745,511
Total Cash
$24,526,000
Total Debt
$3,337,000
Shares Out
14,997,505
Trailing EPS
$-2.00
Book Value
$0.85
ROE
-221.9%
ROA
-89.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,022,000 | -19,182,000 | 6,951,000 | 6,988,000 | — | -17,955,000 |
| Dec 2024 | 0 | -17,048,000 | -11,141,000 | 6,724,000 | 6,216,000 | — | -17,137,000 |
| Dec 2023 | 3,000,000 | -3,129,000 | 5,269,000 | 8,968,000 | 41,262,000 | — | -2,476,000 |
| Dec 2022 | 500,000 | -2,270,368 | -2,682,108 | 858,042 | 38,636,203 | — | -2,075,624 |
TTM Snapshot
Revenues TTM
$43,000
NetIncome TTM
$3,162,000
OpCashFlow TTM
$0
Assets (Latest)
$6,724,000
Forward EPS
$-1.05
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CRVO | CervoMed Inc. | $33.05M | $3.57 | — |
| QUCY | Quantum Cyber N.V. | $30.96M | $1.36 | — |
| KYNB | KYNTRA BIO, INC. | $30.79M | $7.61 | — |
| TVRD | Tvardi Therapeutics, Inc. | $30.77M | $3.28 | — |
| DARE | Dare Bioscience, Inc. | $30.26M | $2.02 | — |
News headlines (Yahoo Finance, 1h cache)
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-07-09 16:10 · Yahoo
Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
2026-06-30 13:01 · Yahoo
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-14 20:20 · Yahoo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
2026-05-13 12:06 · Yahoo
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
2026-04-07 10:00 · Yahoo
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
2026-04-02 20:13 · Yahoo
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-25 20:20 · Yahoo
Serina Therapeutics to Present at the 38th Annual Roth Conference
2026-03-24 10:00 · Yahoo
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-03-18 20:10 · Yahoo
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
2026-02-24 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.